Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00118768 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Combination of Pegylated Interferon Alfa Plus Valopicitabine in Patients With Hepatitis C
A Phase 2 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 2
- Development phase
- 175
- Enrollment target
NCT00118768 is a Phase 2 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 175 participants.
The verdict
NCT00118768, a Phase 2 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 175 participants
- Enrollment target
Study Summary
This Phase II study is being conducted in treatment-naive patients (no previous antiviral therapy for Hepatitis C infection) with genotype-1 chronic hepatitis C to evaluate the safety and effectiveness of valopicitabine alone and together with Pegylated Interferon (a drug approved by the Food and Drug Administration for the treatment of Hepatitis C infection).
Interventions
- DRUG valopicitabine
- DRUG Pegylated Interferon Alfa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 175 participants |
| Start Date | 2005-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00118768
The ClinicalTrials.gov registry entry for NCT00118768 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 175 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which valopicitabine is the first listed.
NCT00118768 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00118768 about?
NCT00118768 is a clinical study titled "A Study to Evaluate the Combination of Pegylated Interferon Alfa Plus Valopicitabine in Patients With Hepatitis C". This Phase II study is being conducted in treatment-naive patients (no previous antiviral therapy for Hepatitis C infection) with genotype-1 chronic hepatitis C to evaluate the safety and effectiveness of valopicitabine alone and together with Pegylated Interferon (a drug approved by the Food and Dr...
What is the current status of trial NCT00118768?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 175 participants. The study started on 2005-08.
What interventions are being tested in trial NCT00118768?
The interventions under investigation include: valopicitabine (DRUG), Pegylated Interferon Alfa (DRUG).
Who is sponsoring clinical trial NCT00118768?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.